The platelet-activating factor antagonist WEB 2170. Its beneficial effect on dog renal allograft survival.
Watson
C J
CJ
Cambridge University Department of Surgery, Addenbrooke's Hospital, United Kingdom.
Luddington
R
R
St John Collier
D G
DG
Calne
R Y
RY
Metcalfe
S M
SM
D000818:Animals; D001381:Azepines / Q000494:pharmacology / Q000627:therapeutic use*; D016572:Cyclosporine / Q000627:therapeutic use*; D004285:Dogs; D004359:Drug Therapy, Combination; D006085:Graft Survival / Q000187:drug effects*; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation / Q000502:physiology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D016019:Survival Analysis; D014184:Transplantation, Homologous / Q000502:physiology; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*
D001381:Azepines; D010972:Platelet Activating Factor; D014230:Triazoles; D016572:Cyclosporine; C063964:bepafant